News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
GlaxoSmithKline (JOBS) Says US Still Reviewing Clot Disorder Drug
September 22, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Sept 19 (Reuters) - U.S. health officials still are reviewing GlaxoSmithKline Plc's proposed clotting disorder drug Promacta, the company said on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
GlaxoSmithKline
MORE ON THIS TOPIC
Vaccines
Pesky ‘Macro Factors’—aka RFK Jr.—Come for Vaccine Pharmas’ Wallets
November 7, 2025
·
4 min read
·
Annalee Armstrong
Regulatory
Wegovy, Casgevy Among Latest FDA Priority Review Voucher Recipients
November 6, 2025
·
3 min read
·
Dan Samorodnitsky
FDA
FDA’s Top Cancer Regulator Declined CDER Directorship
November 6, 2025
·
2 min read
·
Tristan Manalac
Regulatory
‘Chaotic’ HHS Overhaul a Wrecking Ball Toward a Better FDA: Former CIO
November 6, 2025
·
5 min read
·
Jef Akst
